Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • JAK
    (122)
  • Tyrosine Kinases
    (23)
  • Apoptosis
    (22)
  • STAT
    (20)
  • Autophagy
    (7)
  • FLT
    (7)
  • NF-κB
    (5)
  • EGFR
    (4)
  • IL Receptor
    (4)
  • Others
    (46)
Filter
Search Result
Results for "

JAK Inhibitor

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    181
    TargetMol | Inhibitors_Agonists
  • Compound Libraries
    2
    TargetMol | Compound_Libraries
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Natural Products
    16
    TargetMol | Natural_Products
  • Recombinant Protein
    4
    TargetMol | Recombinant_Protein
  • Isotope Products
    2
    TargetMol | Isotope_Products
Pyridone 6
Janus-Associated Kinase Inhibitor I, JAK Inhibitor I, JAK I inhibitor, CMP 6
T3080457081-03-7
Pyridone 6 (JAK Inhibitor)(CMP 6) is a potent and selective inhibitor of JAK1 (IC50=15 nM, murine JAK1), JAK2 (IC50=1 nM), JAK3 (Ki=5 nM), and Tyk2 (IC50=1 nM); displaying significantly weaker affinities (130 nM to 10 mM) for other protein tyrosine kinases.
  • Inquiry Price
Size
QTY
JAK 3 inhibitor IV
ZM 39923 hydrochloride, Jak3 inhibitor IV
T246058753-54-1
JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1 3 inhibitor with pIC50 of 4.4 7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutaminase.
  • Inquiry Price
3-6 months
Size
QTY
Ruxolitinib
INCB018424, (R)-Ruxolitinib
T1829941678-49-5
Ruxolitinib (INCB018424) is a JAK1 2 inhibitor (IC50=3.3 2.8 nM) that is potent and selective. Rixolitinib exhibits antitumor activity and induces autophagy and apoptosis.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Deucravacitinib
BMS-986165
T146871609392-27-9
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12 23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Fedratinib
TG-101348, SAR 302503
T1995936091-26-8
Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Baricitinib
LY3009104, INCB028050
T24851187594-09-7
Baricitinib (INCB028050) is a JAK1 and JAK2 inhibitor (IC50=5.9 5.7 nM) with selective and oral activity. Baricitinib has potential anti-inflammatory, immunomodulatory and anti-tumor activity.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Itacitinib
INCB39110, INCB039110
T39981334298-90-6
Itacitinib (INCB039110) is an orally bioavailable Janus-associated kinase 1 (JAK1) inhibitor with potential antineoplastic activity.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
osunprotafib
Osunprotafib, AC484, AC 484, ABBV-CLS-484
T616992489404-97-7In house
Osunprotafib (ABBV-CLS-484) is a potent, orally bioavailable PTP1B PTPN2 inhibitor in clinical trials for solid tumors. [1] Osunprotafib (ABBV-CLS-484) stimulates the tumor microenvironment and promotes natural killer cell and CD8 T cell function and enhances T cell anti-tumor immunity by enhancing JAK-STAT signaling and reducing T cell dysfunction. [2]
  • Inquiry Price
7-10 days
Size
QTY
TargetMol | Inhibitor Hot
Tofacitinib
Tasocitinib, CP-690550
T6321477600-75-2
Tofacitinib (Tasocitinib) is a Janus kinase inhibitor that inhibits JAK3 2 1 (IC50=1 20 112 nM) and is orally active. Tofacitinib is used for the treatment of moderate to severe rheumatoid arthritis.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Upadacitinib
ABT-494
T75031310726-60-3
Upadacitinib (ABT-494) (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Abrocitinib
PF-04965842
TQ00371622902-68-4
Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29 803 nM for JAK1 2).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
CHZ868
TQ00611895895-38-1
CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.
  • Inquiry Price
7-10 days
Size
QTY
TargetMol | Inhibitor Hot
JAK-IN-5
T117102096999-92-5In house
JAK-IN-5 is a JAK inhibitor.
  • Inquiry Price
6-8 weeks
Size
QTY
TargetMol | Inhibitor Sale
JAK-IN-5 hydrochloride
JAK-IN-5 hydrochloride(2096999-92-5 Free base)
T11710L2751323-21-2In house
JAK-IN-5 hydrochloride is a JAK inhibitor [1].
  • Inquiry Price
1-2 weeks
Size
QTY
JAK-IN-11
R-348
T12549916742-11-5In house
JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.
  • Inquiry Price
6-8 weeks
Size
QTY
JAK-IN-10
T13571916741-98-5In house
JAK-IN-10 is a JAK inhibitor that can be used for the research of dry eye disorders.
  • Inquiry Price
6-8 weeks
Size
QTY
Izencitinib
TD-1473, JNJ-8398
T358982051918-33-1In house
Izencitinib (JNJ-8398) is an orally active and gut-selective JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.
  • Inquiry Price
6-8 weeks
Size
QTY
FLLL32
T68381226895-15-3In house
FLLL32 is an effective JAK2 STAT3 inhibitor (IC50 of <5 μM).
  • Inquiry Price
Size
QTY
JAK-STAT-IN-1
T786071236666-76-4In house
JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.
  • Inquiry Price
6-8weeks
Size
QTY
Tofacitinib Citrate
Tofacitinib (CP-690550) Citrate, Tasocitinib citrate, CP-690550 citrate
T2398540737-29-9
Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1 2 3 (IC50s: 1 20 112 nM).
  • Inquiry Price
Size
QTY
Ruxolitinib phosphate
Ruxolitinib (INCB-18424) phosphate, INCB018424 phosphate, INCB018424, INC424, INC 424 phosphate
T30431092939-17-7
Ruxolitinib phosphate (INCB18424 phosphate) is a JAK1 2 inhibitor with IC50 of 3.3 nM 2.8 nM. Its selectivity for JAK1 2 is more than 130 times that of JAK3.
  • Inquiry Price
Size
QTY
Momelotinib
LM-1149, CYT387, CYT11387
T18491056634-68-4
Momelotinib (LM-1149) is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1 2) with IC50 of 11 nM 18 nM. JAK1 2 inhibitor CYT387 competes with JAK1 2 for ATP binding, which may result in inhibition of JAK1 2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell proliferation in JAK1 2-expressing tumor cells.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Filgotinib
GLPG0634
T19291206161-97-8
Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 values of 10 nM for JAK1, 28 nM for JAK2, 810 nM for JAK3, and 116 nM for TYK2.
  • Inquiry Price
Size
QTY
WP1066
T2156857064-38-1
WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3 5, and ERK1 2, not JAK1 and JAK3. WP1066 has been used in trials studying the treatment of Melanoma, Brain Cancer, Solid Tumors, and Central Nervous System Neoplasms.
  • Inquiry Price
Size
QTY